June 25, 2021 -- Invivoscribe announced the launch of an immune biomarker discovery grant program focused on supporting the development, validation, and deployment of novel applications for their distributed LymphoTrack next-generation sequencing (NGS) products and bioinformatics software.
The company said it launched the program to support learning how its research use only (RUO) LymphoTrack kits and services are being used outside of clinical oncology.
RUO LymphoTrack kits have been used to track the manufacture and treatment of immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies and provide a way to track a subject's immune response to disease processes and to vaccines.
Grants will be awarded to support research and development in academic, government and early-stage commercial laboratories conducting research studies. Proposals will be accepted from qualified laboratories across the world through August 31, 2021, and winners will be announced by September 30, 2021.
Copyright © 2021 scienceboard.net